Company news
Celldex Therapeutics, Inc. (NASDAQ:CLDX) news
Every Celldex Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
August 6, 2026
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
July 21, 2026
Celldex Announces Planned Transition of Chief Financial Officer
July 15, 2026
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at ...
June 14, 2026
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Cl...
June 14, 2026
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Alle...
June 10, 2026
Celldex Reports First Quarter Financial Results and Provides Corporate Update
May 7, 2026
Celldex to Present at Upcoming Investor Conference
April 13, 2026
Celldex Announces Proposed Public Offering of Common Stock
April 1, 2026
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
April 1, 2026
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studie...
March 27, 2026
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients w...
March 1, 2026
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients w...
March 1, 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptom...
February 27, 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptom...
February 27, 2026
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
February 25, 2026
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
February 25, 2026
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
February 23, 2026
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
December 9, 2025
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
November 10, 2025
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Celldex to Present at Upcoming Investor Conferences
November 7, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sust...
November 6, 2025
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria C...
November 6, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sust...
November 6, 2025
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast...
October 30, 2025
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels ...
September 17, 2025
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
September 9, 2025
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
August 19, 2025
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Ur...
June 14, 2025
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
June 12, 2025
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
June 10, 2025
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
June 6, 2025
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult...
May 5, 2025
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 4, 2025
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 3, 2025
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improv...
March 1, 2025
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 27, 2025
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 19, 2024
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflamma...
November 20, 2024
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in C...
October 26, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urtic...
October 25, 2024
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urt...
September 16, 2024
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 29, 2024
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 16, 2024